Change language and content customisation
Find an advisor
Get in touch
Find an office
Jump straight to:
Please enter a search term
We can use your selection to show you more of the content that you’re interested in.
Sign-up to follow topics, sectors, people and also have the option to receive a weekly update of lastest news across your areas of interest.
Got an account already?
Pharmaceutical patent holders that enter into 'pay-for-delay' agreements with generic medicine manufacturers risk breaching EU competition law on three counts, an advocate general to the EU's highest court has said.
Sign-up to receive the latest news, insight and analysis direct to your e-mail inbox